A tissue marker of poor prognosis in clear cell renal cell carcinoma

	Tweet

The search for molecular markers that further advance our knowledge of the biology of renal cell carcinoma (RCC) and assist in evaluating the diagnosis and prognosis of patients remains the subject of intense investigation.

These types of studies have been greatly advanced by the emergence of gene array and tissue microarray technologies. Here, Parker and colleagues out of the Mayo Clinic report on the utility of survivin expression as a marker of prognosis in clear cell RCC. Survivin is an anti-apoptotic protein that demonstrates nuclear expression and was identified as being overexpressed in RCC as a consequence of genomic profiling studies.

Survivin expression was evaluated using computer assisted immunohistochemical analysis in 312 patients with clear cell RCC in a tissue microarray. Of these, 97 (31.3%) demonstrated increased expression of survivin. Overexpression of survivin in this study was classified as ? 2% of cells examined demonstrating increased expression.

Increased expression of survivin was associated with increased tumor size, more advanced tumor stage, increased tumor grade, the presence of coagulative necrosis, the presence of lymph node and distant metastases, and the presence of a venous tumor thrombus. Patients who had overexpression of survivin had an increase risk of death from RCC with a relative risk ratio (RR) of 5.3. The 5 year cancer specific survival for patients with survivin overexpression was 43% versus 87.2% in those without survivin overexpression. In a multivariate analysis that controlled for performance status, TNM stage, grade, and the Mayo SSIGN score, overexpression of survivin remained an independent risk factor for death from RCC. In a subset analysis of 273 patients with localized RCC, increased expression of survivin was associated with an increased risk of cancer progression following nephrectomy, with an RR of 3.9.

This study suggests that expression of the anti-apoptotic protein survivin is associated with a worse outcome in clear cell RCC. One criticism is the definition of overexpression of the protein, which in this study was greater than or equal to 2% of cells evaluated. Mean expression was only 2.3% for the entire population. One wonders of the biologic relevance and utility of a tissue marker that is not found in 98% of the cells in a given tumor.

Cancer 107(1): 37-45, 2006 - UroToday

RELATED STORIES:
Diet can increase risk of kidney cancer   High bread consumption tied to kidney cancer   US approves new drug for advanced kidney cancer   Folic acid may reduce some childhood cancers   Can kidney disease cause cancer?   Early childbirth, big family tied to kidney cancer   Ablation proved as effective as traditional surgery in treating kidney cancer   2 drugs work better together than either alone against kidney cancer   Researchers Find Genetic Secrets to Common Kidney Cancer   Kidney cancer gets new drugs, competition   Novel therapy for metastatic kidney cancer developed at VCU Massey Cancer Center   How Less Can Be More When Treating Some Kidney Cancers   Kidney Cancer Patients May Be Overtreated   Eating fatty fish may ward off kidney cancer   Women fare better than men, but need more blood after kidney cancer surgery   Moderate drinking may lower kidney cancer risk   Kidney removal does not prolong the lives of elderly patients with localized kidney cancer   Percutaneous cryoablation is a safe method for treating kidney tumors   Lead blood levels may increase smokers’ risk for kidney cancer   Majority of kidney cancers diagnosed at earliest stage   Kidney Cancer Patients Unlikely to Respond to Potential Treatment Drug   New drug prolongs survival of advanced kidney cancer

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]